Literature DB >> 25921146

Comparison of three dimensional conformal radiation therapy, intensity modulated radiation therapy and volumetric modulated arc therapy for low radiation exposure of normal tissue in patients with prostate cancer.

Aydin Cakir1, Zuleyha Akgun, Merdan Fayda, Fulya Agaoglu.   

Abstract

Radiotherapy has an important role in the treatment of prostate cancer. Three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) techniques are all applied for this purpose. However, the risk of secondary radiation-induced bladder cancer is significantly elevated in irradiated patients compared surgery-only or watchful waiting groups. There are also reports of risk of secondary cancer with low doses to normal tissues. This study was designed to compare received volumes of low doses among 3D-CRT, IMRT and VMAT techniques for prostate patients. Ten prostate cancer patients were selected retrospectively for this planning study. Treatment plans were generated using 3D-CRT, IMRT and VMAT techniques. Conformity index (CI), homogenity index (HI), receiving 5 Gy of the volume (V5%), receiving 2 Gy of the volume (V2%), receiving 1 Gy of the volume (V1%) and monitor units (MUs) were compared. This study confirms that VMAT has slightly better CI while thev olume of low doses was higher. VMAT had lower MUs than IMRT. 3D-CRT had the lowest MU, CI and HI. If target coverage and normal tissue sparing are comparable between different treatment techniques, the risk of second malignancy should be a important factor in the selection of treatment.

Entities:  

Mesh:

Year:  2015        PMID: 25921146     DOI: 10.7314/apjcp.2015.16.8.3365

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  A comparison of a moderately hypofractionated IMRT planning technique used in a randomised UK external beam radiotherapy trial with an in-house technique for localised prostate cancer.

Authors:  Ian Gleeson
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

2.  Variations in dosimetric distribution and plan complexity with collimator angles in hypofractionated volumetric arc radiotherapy for treating prostate cancer.

Authors:  Ming-Hsien Li; Sheng-Fang Huang; Chih-Chieh Chang; Jang-Chun Lin; Jo-Ting Tsai
Journal:  J Appl Clin Med Phys       Date:  2018-01-11       Impact factor: 2.102

3.  Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis.

Authors:  Wenting Ren; Chao Sun; Ningning Lu; Yingjie Xu; Fei Han; Yue Ping Liu; Jianrong Dai
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

4.  Development of clinical application program for radiotherapy induced cancer risk calculation using Monte Carlo engine in volumetric-modulated arc therapy.

Authors:  Dong-Jin Kang; Young-Joo Shin; Seonghoon Jeong; Jae-Yong Jung; Hakjae Lee; Boram Lee
Journal:  Radiat Oncol       Date:  2021-06-12       Impact factor: 3.481

5.  Triple primary cancer of the head and neck, skin and prostate: A case report and literature review.

Authors:  Nobuyuki Maruyama; Toshiyuki Nakasone; Osao Arakaki; Hirofumi Matsumoto; Tessho Maruyama; Akira Matayoshi; Takahiro Goto; Seiichi Saito; Naoki Yoshimi; Akira Arasaki; Kazuhide Nishihara
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

Review 6.  High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.

Authors:  Shankun Zhao; Qiang Xie; Redian Yang; Jiamin Wang; Chaofeng Zhang; Lianmin Luo; Zhiguo Zhu; Yangzhou Liu; Ermao Li; Zhigang Zhao
Journal:  Cancer Manag Res       Date:  2019-01-10       Impact factor: 3.989

7.  Comparison of Photon-electron and Photon Radiotherapy for Supraclavicular Lymph Nodes of Mastectomy Patients with Left-sided Breast Cancer.

Authors:  Mehran Mohseni; Fatholah Mohaghegh; Nasrin Robatmili; Mohammad Reza Bayatiani; Fatemeh Seif; Nayyer Sadat Mostafavi
Journal:  J Cancer Prev       Date:  2020-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.